Discover the groundbreaking insights into Alzheimer’s Disease as we delve into the potential of neurotrophin growth factors and their receptors as novel blood biomarkers, unlocking new avenues for early detection and therapeutic strategies.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Neurotrophin growth factors and their receptors as promising blood biomarkers for Alzheimer’s Disease: a gene expression analysis study.
Asadi et al., Mol Biol Rep 2024
DOI: 10.1007/s11033-023-08959-4
Key Findings:
- The study focused on the mRNA expression levels of neurotrophin growth factors and their receptors in blood samples from 50 Alzheimer’s disease (AD) patients and 50 healthy controls.
- Using quantitative PCR and Bayesian regression, the research found significantly lower expression levels of NTRK2, TrkA, TrkC, and BDNF in AD patients (p-value < 0.05).
- BDNF showed the most substantial decrease and had the highest diagnostic potential with an AUC of 0.76, 70% sensitivity, and 66% specificity.
- There was a positive correlation between the expression of these genes.
Importance:
The study suggests that the decreased expression of these neurotrophin-related genes could serve as potential biomarkers for AD diagnosis and treatment. This contributes to the understanding of AD progression and opens avenues for new therapeutic strategies.
Contribution to Literature:
This research adds to the current literature by providing evidence that specific neurotrophin growth factors and their receptors are downregulated in AD and that their expression levels correlate with disease presence, which could aid in the development of non-invasive diagnostic tools for AD.